

HOLD TP: Rs 375 | ¥ 2%

AMBUJA CEMENTS

Cement

04 May 2023

Soft realisations weigh on margins

- Q4 revenue growth muted at 8% YoY on tepid realisations and limited volumes owing to a labour strike
- EBITDA margin down 160bps YoY despite savings from softer fuel cost and logistics cost control
- We cut FY24/FY25 EPS by 5%/4%, translating to a revised TP of Rs 375 (vs. Rs 387); maintain HOLD as positives priced in

Milind Raginwar | Yash Thakur research@bobcaps.in

Realisations soft: ACEM reported muted Q4FY23 revenue growth of 8% YoY (+3% QoQ) to Rs 42.6bn primarily owing to weak realisations. Volumes grew 8% YoY (+5% QoQ) to 8.1mn tonnes, while realisations stayed flat YoY (-2% QoQ) at Rs 5,255/t. The impact of a labour strike at the company's Himachal Pradesh unit was partly countered by clinker shift from Rajasthan to cater North and supported by an increase in blended cement).

Operating cost pressure easing: Operating cost rose 2% YoY to Rs 4,282/t (-6% QoQ) as energy cost (adj to RM cost) grew 13% YoY (-8% QoQ) to Rs 2,350/t, with the clinker factor down from 62.5% to 60.6%. Kiln cost fell 10%, from 2.3/kcal to Rs 2.1/kcal on a better fuel mix and group coal procurement synergies. RM cost rose 51% YoY (+11% QoQ) to Rs 1,073/t due to higher external purchases, logistics cost fell 1% YoY (+6% QoQ) to Rs 1,151/t on better direct dispatches (78% from 64%) and a higher rail mix (30% from 26%). Other expenditure at Rs 4.6bn fell ~15% YoY/ QoQ.

EBITDA margin contracts YoY: EBITDA at Rs 7.9bn was flat YoY (+26% QoQ) due to poor realisations. EBITDA margin shrank 160bps YoY (+335bps QoQ) to 18.5% and EBITDA/t declined 8% YoY (+20% QoQ) to Rs 973/t. PAT was flat YoY (+36% QoQ) at Rs 5bn. Excluding restructuring cost of Rs 0.8bn, PAT grew 18% YoY (+36% QoQ).

Capacity expansion plans: ACEM announced no plans beyond the greenfield capacity additions at Chandrapur (Maharashtra), Bhatpara (W. Bengal) and Mundra (Gujarat), where commissioning is targeted by Q2FY25 – an ambitious schedule, in our view, given that equipment ordering is yet to commence.

Maintain HOLD: ACEM's operating efficiency drive is a key positive, though capacity building is unlikely to contribute meaningfully before FY25. The stock is currently trading at 13x FY25E EV/EBITDA. We cut our FY24/FY25 EPS estimates by 5%/4% to bake in ACEM's accounting year change, leading to a revised SOTP-based TP of Rs 375 (vs. Rs 387), set at an unchanged 13x FY25E standalone EV/EBITDA. Our TP implies a replacement cost of Rs 14bn/mt (consolidated capacity) – 2x premium to the industry average. Upsides appear capped at current valuations and hence we retain HOLD.

Key changes

Та	rget	Rating	
	▼	< ▶	

Ticker/Price	ACEM IN/Rs 384
Market cap	US\$ 9.3bn
Free float	37%
3M ADV	US\$ 56.9mn
52wk high/low	Rs 598/Rs 315
Promoter/FPI/DII	63%/11%/17%

Source: NSE | Price as of 3 May 2023

Key financials

Y/E 31 Mar	FY23P	FY24E	FY25E
Total revenue (Rs mn)	3,84,062	3,70,071	4,16,513
EBITDA (Rs mn)	51,223	55,789	68,431
Adj. net profit (Rs mn)	29,024	25,404	29,899
Adj. EPS (Rs)	11.7	12.8	15.1
Consensus EPS (Rs)	11.7	15.6	17.9
Adj. ROAE (%)	9.3	7.6	9.0
Adj. P/E (x)	32.8	30.0	25.5
EV/EBITDA (x)	14.2	9.8	7.6
Adj. EPS growth (%)	(20.0)	9.4	17.7

Source: Company, Bloomberg, BOBCAPS Research \mid P – Provisional \mid FY23 is for 15 months due to a change in year-end from December to March

Stock performance



Source: NSE





Fig 1 – Earnings call highlights

Parameter	Q4FY23	Q3FY23	Our view
Volume and Realisation	The share of blended cement increased to 92% in Q4 from 91% in Q3. Premium products formed 22% of trade sales. ACEM aims to increase B2B segment share from 21% to 25% by FY27 and raise premium product share from 22% to 29-30%.	NA	ACEM has traditionally been a trade business company. However, infrastructure-driven growth will imply a shift towards non-trade business or loss of market share.
Margins	Initiatives to improve EBITDA/t by Rs 300-400/t in FY24 include raising waste heat recovery systems, renewable capacity, alternate fuel and raw material use, and undertaking fly ash sourcing of 14mt. Captive coal mine capacity at Gare Palma of 1.2mtpa and Dahegaon Bawri of 2mtpa will cater to 50% of current demand for kiln coal. This is guided to lower costs by Rs 250/t. With respect to freight and forwarding, ACEM aims to optimise warehousing by increasing direct dispatches and improving the rail-road mix. It is also exploring sea transportation options by procuring 10 rakes, of which 1 has already commenced. Management expects these initiatives to yield cost reduction of Rs 100/t.	Management expects EBITDA/t to rise to Rs 1,000 in the next couple of quarters backed by cost optimisation. This will be led by: (i) a reduction in fuel cost (kiln fuel cost has fallen substantially QoQ from Rs 2.8/kcal to Rs 2.5/kcal, resulting in a 14% sequential drop in overall fuel cost in Q3FY23), and (ii) lower logistics cost (on account of operational synergies with ACC and Adani Logistics, leading to rationalising of the warehouse network).	Operating efficiency improvement driven by fuel cost easing, better logistics and warehouse management, and control over other expenses will continue to help ACEM improve earnings. However, muted realisations can be a cause for concern.
Capacity	ACEM has a five-year plan to add 40mt of clinker (9 lines brownfield and Mundra greenfield). A few clinker and grinding units are to be commissioned by Q2FY25.	NA	The medium-term expansion plan looks intact. However, any delay in capacity addition will mean a limited contribution in FY25.
Green Energy	ACEM plans to increase WHRS capacity from 80MW to 175MW by FY24, raise the share of alternate fuel and raw material in the fuel mix from 8.8% to 30% (midterm) and 15% by end-FY24, and increase renewable power by 200MW (solar) by FY24.	Management plans to increase WHRS capacity to 190MW by Mar'25 from the existing 65MW as of Dec'22 as part of its target of achieving a 30% thermal substitution rate by 2027.	A slow start in non-thermal energy initiatives is proving to be a pain point for ACEM, though the impact will be lower in the medium term.
Capex	Capex for FY24 is guided at Rs 7.2bn. With respect to doubling capacity from 70mt to 140mt, capex will total Rs 460bn which will be funded through internal accruals.	As a part of the growth strategy, Rs 100bn has been earmarked towards WHRS, debottlenecking, greenfield clinker grinding units and a brownfield kiln to be undertaken over the next 18 months.	Defined capex needs faster execution to retain market share in a strong demand recovery scenario.

Source: Company, BOBCAPS Research



Fig 2 - Key metrics

(Rs)	Q4FY23	Q4FY22	YoY (%)	Q3FY23	QoQ (%)
Volumes (mn mt)	8.1	7.5	8.1	7.7	5.2
Cement realisations (Rs/mt)	5,255	5,241	0.3	5,362	(2.0)
Operating costs (Rs/mt)	4,282	4,185	2.3	4,549	(5.9)
EBITDA (Rs/mt)	973	1,055	(7.8)	813	19.7

Source: Company, BOBCAPS Research |


Fig 3 - Quarterly performance

(Rs mn)	Q4FY23	Q4FY22	YoY (%)	Q3FY23	QoQ (%)
Net Sales	42,563	39,252	8.4	41,285	3.1
Expenditure					
Change in stock	1,206	696	73.4	1,632	(26.1)
Raw material	3,590	3,117	15.2	3,782	(5.1)
Purchased products	3,899	1,499	160.1	2,066	88.7
Power & fuel	10,343	10,309	0.3	12,111	(14.6)
Freight	9,326	8,682	7.4	8,362	11.5
Employee costs	1,680	1,529	9.9	1,595	5.3
Other expenditure	4,637	5,517	(15.9)	5,475	(15.3)
Total Operating Expenses	34,681	31,348	10.6	35,024	(1.0)
EBITDA	7,883	7,904	(0.3)	6,261	25.9
EBITDA margin (%)	18.5	20.1	(162bps)	15.2	335bps
Other Income	1,740	367	373.9	890	95.5
Interest	335	214	56.5	253	32.6
Depreciation	2,047	1,515	35.1	1,648	24.2
PBT	7,241	6,543	10.7	5,250	37.9
Non-recurring items	(807)	0	-	(614)	NM
PBT (after non-recurring items)	6,434	6,543	(1.7)	4,637	38.7
Tax	1,410	1,591	(11.4)	947	48.8
Reported PAT	5,024	4,952	1.5	3,690	36.2
Adjusted PAT	5,831	4,952	17.8	4,303	35.5
NPM (%)	13.7	12.6	108bps	10.4	328bps
Adjusted EPS (Rs)	2.9	2.5	17.8	2.2	35.5

Source: Company, BOBCAPS Research




Fig 4 - Volume gains hit by strike in one unit




Source: Company, BOBCAPS Research | Note: ACC has changed its accounting Y/E from Dec to Mar; thus, FY23 consists of 5 quarters

Fig 6 – Muted pricing offsets cost savings, restricting EBITDA gains




Source: Company, BOBCAPS Research

Fig 8 - Freight cost savings on the rise




Source: Company, BOBCAPS Research

Fig 5 - Realisations muted despite slower volume growth




Source: Company, BOBCAPS Research

Fig 7 – Operating cost control driven by energy cost savings



Source: Company, BOBCAPS Research

Fig 9 - Energy cost savings to continue in near term



Source: Company, BOBCAPS Research



Valuation methodology

ACEM's operating efficiency drive is a key positive, though capacity building is unlikely to contribute meaningfully before FY25 given that equipment ordering is yet to commence. The stock is currently trading at 13x FY25E EV/EBITDA. Factoring in the change in ACEM's accounting year-end from December to March, we lower our FY24/FY25 EBITDA estimates by ~3% each and EPS estimates by 5%/4%. This yields a revised SOTP-based TP of Rs 375 (vs. Rs 387).

We continue to value the standalone business at 13x FY25E EV/EBITDA with ACEM's 50% stake in ACC valued at 10% holding company discount. Our TP implies a replacement cost of Rs 14bn/mt (consolidated capacity) – 2x premium to the industry average. Upsides appear capped at current valuations and we hence retain HOLD.

Fig 10 - Revised estimates

(Rs mn)	New	ı	Old	Ī	Change (%)		
	FY24E	FY25E	FY24E	FY25E	FY24E	FY25E	
Revenue	370,071	416,513	373,473	420,333	(0.9)	(0.9)	
EBITDA	55,789	68,431	57,656	70,196	(3.2)	(2.5)	
Adj PAT	25,404	29,899	26,720	31,144	(4.9)	(4.0)	
Adj EPS (Rs)	12.8	15.1	13.5	15.7	(5.2)	(3.8)	

Source: BOBCAPS Research

Fig 11 - Key assumptions

Parameter	CY21	FY23	FY24E	FY25E
Volumes (mt)	27.2	37.8	32.6	35.6
Realisations (Rs/mt)	5,060	5,287	5,369	5,530
Operating costs (Rs/mt)	3,892	4,442	4,448	4,580
EBITDA/mt (Rs)	1,247	845	1,022	1,048

Source: Company, BOBCAPS Research

Fig 12 - Valuation summary

Business (Rs mn)	FY25E
Target EV/EBITDA (x)	13
EBITDA (Rs mn)	37,295
Target EV (Rs mn)	484,835
Total EV	484,835
Net debt	(63,177)
Target market capitalisation	548,012
ACEM's standalone value (Rs/sh) (A)	275.9
Weighted average shares (mn)	1,986
ACC Target M-cap	438,930
ACEM Holding in ACC (50.05%)	219,465
Holding Co discount (10%)	21,946
ACEM Holding in ACC (50.05%) (Post Hold Co Discount)	197,518.5
Total Equity Shares O/S (mn)	1,986
ACEM's value in ACC (Rs/sh) (B)	99.5
Target price (Rs/sh) (A+B)	375.4

Source: BOBCAPS Research



Fig 13 – Peer comparison

Ticker Rating TP		TP _	EV/EBITDA (x)		EV/tonne (US\$)		ROE (%)			ROCE (%)						
Tickei	icker Rating (Rs)	(Rs)	Rating ((Rs)	FY23	FY24E	FY25E	FY23	FY24E	FY25E	FY23	FY24E	FY25E	FY23	FY24E	FY25E
ACEM IN	HOLD	375	14.2	9.8	7.6	286	215	204	5.2	6.4	7.0	9.2	11.1	13.0		
ACC IN	HOLD	1,964	16.4	12.2	8.1	114	91	83	7.9	7.9	11.2	7.9	10.8	14.5		
UTCEM IN	BUY	8,678	21.0	16.9	13.6	209	211	211	9.7	12.0	14.5	12.8	15.8	18.3		
SRCM IN	HOLD	24,656	28.0	19.5	15.2	206	204	200	6.4	10.8	13.6	9.2	14.6	18.0		

Source: Company, BOBCAPS Research

Key risks

Key upside risks to our estimates are:

- large capex announcements,
- strong pricing tailwinds in ACEM's key regions, and
- above-estimated cost savings.

Key downside risks are:

- slower-than-expected capacity growth, and
- continued high cost inflation, especially for fuel.

Sector recommendation snapshot

Company	Ticker	Market Cap (US\$ bn)	Price (Rs)	Target (Rs)	Rating
ACC	ACC IN	4.0	1,744	1,964	HOLD
Ambuja Cements	ACEM IN	9.3	384	375	HOLD
Dalmia Bharat	DALBHARA IN	4.5	2,001	1,917	HOLD
JK Cement	JKCE IN	2.8	2,990	3,371	BUY
JK Lakshmi Cement	JKLC IN	1.1	777	551	SELL
Orient Cement	ORCMNT IN	0.3	125	140	HOLD
Shree Cement	SRCM IN	10.7	24,259	24,656	HOLD
Star Cement	STRCEM IN	0.6	126	138	BUY
The Ramco Cements	TRCL IN	2.2	748	534	SELL
Ultratech Cement	UTCEM IN	26.5	7,507	8,678	BUY

Source: BOBCAPS Research, NSE | Price as of 3 May 2023



Financials

Income Statement					
Y/E 31 Mar (Rs mn)	CY20A	CY21A	FY23P	FY24E	FY25E
Total revenue	2,41,160	2,85,926	3,84,062	3,70,071	4,16,513
EBITDA	50,056	62,103	51,223	55,789	68,431
Depreciation	(11,618)	(11,525)	(16,447)	(12,875)	(14,059)
EBIT	42,934	54,103	42,154	45,797	57,240
Net interest inc./(exp.)	(1,402)	(1,457)	(1,949)	(1,735)	(1,665)
Other inc./(exp.)	4,496	3,524	7,377	2,883	2,868
Exceptional items	(1,760)	0	0	0	0
EBT	39,772	52,646	40,205	44,062	55,575
Income taxes	(8,848)	(14,534)	(7,051)	(13,769)	(17,166)
Extraordinary items	0	0	0	0	0
Min. int./Inc. from assoc.	(7,270)	(9,104)	(4,130)	(4,888)	(8,510)
Reported net profit	23,654	29,007	29,024	25,404	29,899
Adjustments	1,760	0	0	0	0
Adjusted net profit	25,415	29,007	29,024	25,404	29,899
Balance Sheet					
Y/E 31 Mar (Rs mn)	CY20A	CY21A	FY23P	FY24E	FY25E
Accounts payables	58,452	68,242	75,066	82,572	90,830
Other current liabilities	33,941	43,791	40,162	46.458	47,851
Provisions	2,926	3,062	2,795	2,935	3,082
Debt funds	4,644	4,429	4,622	4,517	4,562
Other liabilities	6,260	7,562	7,004	7,144	7,287
Equity capital	3,971	3,971	3,971	3,971	3,971
Reserves & surplus	2,23,605	2,49,566	3,13,011	3,31,902	3,55,288
Shareholders' fund	2,23,003	3,24,988	3,87,566	4,11,570	4,43,690
Total liab. and equities	3,97,207	4,52,073	5,17,215	5,55,195	5,97,301
Cash and cash eq.	89,356	1,16,943	39,960	2,20,341	2,49,452
Accounts receivables	5,611	6,458	11,544	10,646	11,982
Inventories	16,486	27,380	32,728	26,361	29,669
Other current assets	54,047	54,811	1,61,329	73,231	84,900
Investments	2,629	1,981	(8,213)	88	88
Net fixed assets	1,15,565	1,32,622	1,21,349	1,14,182	1,06,060
CWIP	1,10,996	1,09,160	1,55,804	1,07,634	1,12,441
Intangible assets	2,518	2,717	2,714	2,712	2,709
Deferred tax assets, net	2,510	0	2,714	0	2,703
Other assets	0	0	0	0	0
Total assets	3,97,207	4,52,073	5,17,215	5,55,195	5,97,301
Cash Flows Y/E 31 Mar (Rs mn)	CY20A	CY21A	FY23P	FY24E	FY25E
Cash flow from operations	49,551	57,534	30,954	1,52,612	46,095
Capital expenditures	(19,050)	(26,271)	(51,815)	42,464	(10,742)
Change in investments	6,741	7,547	(155)	(13,475)	(7,762)
Other investing cash flows	0,711	0	0	0	(1,102)
Cash flow from investing	(12,309)	(18,724)	(51,970)	28,989	(18,503)
Equities issued/Others	(654)	(1,063)	(4,996)	225	225
Debt raised/repaid	3,869	(215)	193	(106)	45
Interest expenses	0,000	0	0	0	0
Dividends paid	(36,738)	(2,070)	(6,513)	(6,513)	(6,513)
Other financing cash flows	(695)	(976)	(55,000)	(0,513)	(0,515)
Cash flow from financing	(34,218)	(4,324)	(66,316)	(6,394)	(6,243)
Chg in cash & cash eq.	3,024	34,486	(87,332)	1,75,207	21,349
Closing cash & cash eq.					
Oloshiy cash & cash eq.	89,356	1,16,943	39,960	2,20,342	2,49,452

Per Share					
Y/E 31 Mar (Rs)	CY20A	CY21A	FY23P	FY24E	FY25E
Reported EPS	11.9	14.6	11.7	12.8	15.1
Adjusted EPS	12.8	14.6	11.7	12.8	15.1
Dividend per share	18.5	1.0	2.2	2.8	2.8
Book value per share	146.5	163.7	195.2	207.3	223.4
Valuations Ratios					
Y/E 31 Mar (x)	CY20A	CY21A	FY23P	FY24E	FY25E
EV/Sales	2.8	2.3	1.9	1.5	1.2
EV/EBITDA	13.5	10.5	14.2	9.8	7.6
Adjusted P/E	30.0	26.3	32.8	30.0	25.5
P/BV	2.6	2.3	2.0	1.9	1.7
DuPont Analysis					
Y/E 31 Mar (%)	CY20A	CY21A	FY23P	FY24E	FY25E
Tax burden (Net profit/PBT)	77.8	72.4	82.5	68.7	69.
Interest burden (PBT/EBIT)	96.7	97.3	95.4	96.2	97.
EBIT margin (EBIT/Revenue)	17.8	18.9	11.0	12.4	13.
Asset turnover (Rev./Avg TA)	60.4	67.3	79.2	69.0	72.3
Leverage (Avg TA/Avg Equity)	1.4	1.4	1.4	1.3	1.3
Adjusted ROAE	11.0	12.4	9.3	7.6	9.0
Ratio Analysis					
Y/E 31 Mar	CY20A	CY21A	FY23P	FY24E	FY25E
YoY growth (%)					
Revenue	(9.2)	18.6	7.5	20.4	12.
EBITDA	8.9	24.1	(34.0)	36.1	22.7
Adjusted EPS	21.3	14.1	(20.0)	9.4	17.
Profitability & Return ratios (%)					
EBITDA margin	20.4	21.4	13.2	14.8	16.2
EBIT margin	17.5	18.6	10.8	12.2	13.
Adjusted profit margin	10.5	10.1	7.6	6.9	7.5
Adjusted ROAE	11.0	12.4	9.3	7.6	9.0
ROCE	14.1	16.9	9.2	11.1	13.0
Working capital days (days)					
Receivables	8	8	14	11	1
Inventory	25	35	39	26	2
Payables	109	109	101	94	9;
Ratios (x)					

0.0 Source: Company, BOBCAPS Research | Note: TA = Total Assets | | FY23 is for 15 months due to a change in accounting year-end from December to March

1.3

1.7

30.6

Gross asset turnover Current ratio

Adjusted debt/equity

Net interest coverage ratio

1.4

1.8

37.1

0.0

1.8

2.1

21.6

0.0

1.7

2.5

26.4

0.0

1.9

2.7

34.4

0.0



NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

Disclaimer

Name of the Research Entity: BOB Capital Markets Limited

Registered office Address: 1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051

SEBI Research Analyst Registration No: INH000000040 valid till 03 February 2025

Brand Name: BOBCAPS

Trade Name: www.barodaetrade.com CIN: U65999MH1996GOI098009





Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY - Expected return >+15%

HOLD - Expected return from -6% to +15%

SELL - Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Ratings and Target Price (3-year history): AMBUJA CEMENTS (ACEM IN)



B - Buy, H - Hold, S - Sell, A - Add, R - Reduce

Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

AMBUJA CEMENTS



The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in the document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construct this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "Losses") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK are result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd) ("MSL") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as "MAYBANK"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.